- Roth Capital downgrades recent IPO Kindred Biosciences (NASDAQ:KIN) to Neutral due to valuation with a price target of $25. Shares currently exchange hands at $23.50.
- KIN debuted in December. Share peaked at $26.89 on February 27, up 125% from its opening day close of $11.95.
- 28 mutual funds have positions.
Kindred downgraded
Recommended For You
More Trending News
About ELAN Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| ELAN | - | - |
| Elanco Animal Health Incorporated | ||